
Roumai Medical is a biotechnology company focused on making regenerative medicine accessible globally. They leverage two core platforms: Advanced Materials, which are bioengineered materials designed to support cell growth, repair tissues, and accelerate healing; and Synthetic Biology, which involves precisely controlling biological systems for therapeutic innovation. Their product lines include MedTech with RegeneVessel (a regenerative implant), Cell Bank for immune and stem cell storage, Beauty Bank for cosmetic and medical aesthetic collagen treatments (like MyColla and Exosomes), and Swiss Longevity Project focusing on metabolism, cellular repair, and anti-aging with products like NAD+ and NMN, and Swiss Regeneration Factor. The company aims to repair and rejuvenate the body through innovative treatments, improving quality and expectancy of life.

Roumai Medical is a biotechnology company focused on making regenerative medicine accessible globally. They leverage two core platforms: Advanced Materials, which are bioengineered materials designed to support cell growth, repair tissues, and accelerate healing; and Synthetic Biology, which involves precisely controlling biological systems for therapeutic innovation. Their product lines include MedTech with RegeneVessel (a regenerative implant), Cell Bank for immune and stem cell storage, Beauty Bank for cosmetic and medical aesthetic collagen treatments (like MyColla and Exosomes), and Swiss Longevity Project focusing on metabolism, cellular repair, and anti-aging with products like NAD+ and NMN, and Swiss Regeneration Factor. The company aims to repair and rejuvenate the body through innovative treatments, improving quality and expectancy of life.
Founded: 2021
Headquarters / Footprint: Lausanne (EPFL Innovation Park) and Shenzhen (Nanshan iPark)
Core platforms: Advanced Materials; Synthetic Biology
Flagship product: RegeneVessel (tissue-engineered blood vessel)
Recent funding: Non-equity assistance round on 2024-02-12 led by Innovaud
Founders / Leadership: Shiyu Cheng (CEO); Ivan Istomin (COO)
Regenerative medicine, tissue engineering, cell banking, and longevity/anti-aging therapeutics.
2021
Biotechnology / Medical devices
“Innovaud (lead investor for Feb 12, 2024 non-equity assistance round)”